Colossal Biosciences

Biotech / BiopharmaAustinFounded 2021Website

#163 by valuationHype60

Colossal Biosciences is a bioscience and genetic engineering company focused on restoring extinct species and protecting endangered ones. Utilizing advanced gene editing technologies like CRISPR, the company aims to revive species such as the woolly mammoth and enhance ecosystems. Through innovative approaches, Colossal seeks to address the urgent challenges of extinction and biodiversity loss.

Founded by Kent Wakeford (Co-Founder, COO, Advisor), Vincent Cordero (Investor & Co-Founder), Ben Lamm (Co-Founder & CEO), George Church (Co-Founder)

Blended valuation$5.2B$5.1B secondary

Valuation history

Weekly blended valuation with priced funding rounds marked on the timeline.

$11.1B

blended valuationfunding round

Feb 28, 2022$0Oct 5, 2026

All rounds

7 funding rounds, newest first.

Round	Announced	Raised	Post-money
Series C	Feb 3, 2026	$60M	—
Series C	Sep 18, 2025	$120M	$10.3B
Series C	Jan 15, 2025	$200M	$10.2B
Round	Nov 13, 2023	$10.5M	—
Series B	Jan 31, 2023	$162.6M	$1B

Join Legion to view all 7 rounds.Sign in to Legion

Investors

34 investors across all rounds.

UI
US Innovative Technology Fund
BC
Bold Capital Partners
BC
Breyer Capital
AB
Animoca Brands
BV
Boost VC
DA
Draper Associates
BV
Builders VC
CF
Capital Factory
EV
Evolution VC Partners
HC
HOF Capital

Only Legion members can view the full investor roster. Sign in to Legion

Secondary market activity

Recent buy and sell interest for Colossal Biosciences shares on the secondary market.

Kind	Implied valuation	Price / share	Date
Quote	$5.1B	—	Oct 6, 2026
Quote	$5B	$11.91	Sep 29, 2026
Quote	$5.4B	$12.97	Jun 29, 2026

Invest in the private markets on Legion

Registered users see full trading activity, every investor, rankings, and live deals.

Get started

Data as of Oct 16, 2026. Valuations are estimates blended from primary and secondary-market signals — not investment advice.